Zhaoke Ophthalmology Management
Management criteria checks 3/4
Zhaoke Ophthalmology's CEO is Benjamin Li, appointed in Jan 2017, has a tenure of 7.5 years. total yearly compensation is CN¥17.35M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth HK$228.35K. The average tenure of the management team and the board of directors is 3.3 years and 3.4 years respectively.
Key information
Benjamin Li
Chief executive officer
CN¥17.4m
Total compensation
CEO salary percentage | 40.2% |
CEO tenure | 7.5yrs |
CEO ownership | 0.03% |
Management average tenure | 3.3yrs |
Board average tenure | 3.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | CN¥17m | CN¥7m | -CN¥385m |
Sep 30 2023 | n/a | n/a | -CN¥433m |
Jun 30 2023 | n/a | n/a | -CN¥480m |
Mar 31 2023 | n/a | n/a | -CN¥444m |
Dec 31 2022 | CN¥21m | CN¥6m | -CN¥407m |
Sep 30 2022 | n/a | n/a | -CN¥355m |
Jun 30 2022 | n/a | n/a | -CN¥303m |
Mar 31 2022 | n/a | n/a | -CN¥1b |
Dec 31 2021 | CN¥39m | CN¥6m | -CN¥2b |
Sep 30 2021 | n/a | n/a | -CN¥2b |
Jun 30 2021 | n/a | n/a | -CN¥3b |
Mar 31 2021 | n/a | n/a | -CN¥2b |
Dec 31 2020 | CN¥3m | n/a | -CN¥727m |
Compensation vs Market: Benjamin's total compensation ($USD2.39M) is above average for companies of similar size in the Hong Kong market ($USD232.79K).
Compensation vs Earnings: Benjamin's compensation has been consistent with company performance over the past year.
CEO
Benjamin Li (61 yo)
7.5yrs
Tenure
CN¥17,354,000
Compensation
Dr. Xiaoyi Li, also known as Benjamin, Ph.D. is Founder of Lee's Pharmaceutical Holdings Limited and serves as its Executive Director & Senior Adviser since April 29, 2021. He serves as the Chief Executive...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman of the Board & CEO | 7.5yrs | CN¥17.35m | 0.031% CN¥ 228.4k | |
COO & Executive Director | less than a year | CN¥1.82m | no data | |
President & Chief Scientific Officer | 5.3yrs | no data | no data | |
Group General Counsel | 2.8yrs | no data | no data | |
Senior Vice President of Corporate Development | 5.5yrs | no data | no data | |
Senior Vice President of Sales & Marketing | 2.5yrs | no data | no data | |
Chief Medical Officer | 3.1yrs | no data | no data | |
Senior Vice President of Manufacturing & Logistics | 2.5yrs | no data | no data | |
Group Head of Regulatory Affairs | 3.5yrs | no data | no data | |
VP of Financial Dept. & Company Secretary | 4.8yrs | no data | no data |
3.3yrs
Average Tenure
49yo
Average Age
Experienced Management: 6622's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman of the Board & CEO | 7.5yrs | CN¥17.35m | 0.031% CN¥ 228.4k | |
COO & Executive Director | 3.8yrs | CN¥1.82m | no data | |
Independent Non-Executive Director | 3.3yrs | CN¥422.00k | no data | |
Independent Non-Executive Director | 3.3yrs | CN¥422.00k | no data | |
Non Executive Director | 3.4yrs | CN¥422.00k | no data | |
Independent Non-Executive Director | 2.1yrs | CN¥422.00k | no data | |
Non-Executive Director | 7.4yrs | CN¥422.00k | 0.0043% CN¥ 32.2k |
3.4yrs
Average Tenure
61yo
Average Age
Experienced Board: 6622's board of directors are considered experienced (3.4 years average tenure).